Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates
Business Wire•03/11/2026•07:30 ET
0
Key Highlights
- ➤Cash, equivalents and marketable securities rose to $174.8 million as of September 30, 2026
- ➤Phase 2 PIK-201 topline endometrial cancer results expected by year-end 2026
- ➤FDA granted Fast Track designation to PIKTOR plus paclitaxel in advanced endometrial cancer
- ➤Third-quarter net loss widened to $20.4 million from $4.6 million year over year
- ➤Initial PIK-101 breast cancer safety and efficacy data expected in 2027
Expert Statements
Anand Parikh, Chief Executive Officer of Faeth Therapeutics
“Since our last quarterly update, we presented PK/PD analysis that informed the PIKTOR dose in our Phase 2 PIK-201 trial and received Fast Track designation for PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer”
Anand Parikh, Chief Executive Officer of Faeth Therapeutics
“The PAM pathway is dysregulated in up to 50% of solid tumors, and feedback reactivation and resistance mutations may limit single-node inhibitors.”
Anand Parikh, Chief Executive Officer of Faeth Therapeutics
“We designed PIKTOR, an all-oral, multi-node inhibitor, to address those limitations, and we believe it has the potential to give patients a differentiated treatment option.”
Anand Parikh, Chief Executive Officer of Faeth Therapeutics
“We look forward to reading out topline data from our Phase 2 PIK-201 trial in endometrial cancer by year-end, and to reporting initial safety and efficacy data from our PIK-101 trial in HR+/HER2- breast cancer in 2027.”
Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates
* Topline results from the Phase 2 PIK-201 trial in endometrial cancer expected by year-end
Get started
Create a free account to read the full story.